Richmond Pharmacology Announces Promotions of Dr Matej Goricar and Dr Amir Majid

Richmond is pleased to announce the promotions of Dr Matej Goricar and Dr Amir Majid to senior roles within the Medical Directorate as Associate Medical Directors. These advancements reflect their exceptional contributions, expertise, and commitment to advancing clinical research.

Dr Matej Goricar joined Richmond in 2022 and with previous experience in pharmacogenomics and clinical trials, has played a pivotal role in advancing our capabilities in precision medicine. He holds a MD from the University of Ljubljana and has been instrumental in leading early-phase, genome-editing, and rare disease clinical trials, enhancing Richmond's research portfolio.

Dr Amir Majid, with his experience in anaesthesia and clinical pharmacology, has significantly contributed to Richmond Pharmacology's success in early-phase and complex trials. As a dynamic leader, he has driven excellence across multiple therapeutic areas and demonstrated unwavering commitment to volunteer safety and trial integrity.

Dr Goricar commented: "I am honoured to step into this new role at Richmond Pharmacology. I look forward to working closely with our teams to further develop our innovative approach to clinical trials, ensuring we remain at the forefront of early-phase research."

Dr Majid added: "I am excited to take on this leadership role and contribute to the continuous improvement of our research and operations. Together, we will build on Richmond's strong foundation to deliver exceptional results for our trial sponsors and participants."

-Ends-

Notes to Editor: 

About Richmond 

Richmond is a leading UK CRO, founded in 2001, specialising in first-in-human studies and adaptive clinical trials for gene editing and gene silencing therapies. In 2021 it was first in the world to treat a patient with the Nobel Prize-winning CRISPR-cas9 gene editing tool and currently has more patients undergoing cutting-edge genetic trials than any other clinic in the world. It has completed more than 500 early phase studies and helped deliver 30 medicines to market - including drugs for heart failure, hypertension and cancer. Clients include top 10 pharma, genetic engineering and biotech companies from around the world, especially Europe, the USA and Japan. In 2020, Richmond founded the Richmond Research Institute to advance understanding of under-researched diseases. 

For more information, please contact Linda Rose: linda@denhams.digital 07788 592842